1
|
Sortica DA, Crispim D, Bauer AC, Nique PS, Nicoletto BB, Crestani RP, Staehler JT, Manfro RC, Canani LH. K121Q polymorphism in the Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 gene is associated with acute kidney rejection. PLoS One 2019; 14:e0219062. [PMID: 31318911 PMCID: PMC6639061 DOI: 10.1371/journal.pone.0219062] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Accepted: 06/15/2019] [Indexed: 12/31/2022] Open
Abstract
The identification of risk factors for acute rejection (AR) may lead to strategies to improve success of kidney transplantation. Ectonucleotidases are ectoenzymes that hydrolyze extracellular nucleotides into nucleosides, modulating the purinergic signaling. Some members of the Ectonucleotidase family have been linked to transplant rejection processes. However, the association of Ectonucleotide Pyrophosphatase / Phosphodiesterase 1 (ENPP1) with AR has not yet been evaluated. The aim of this study was to evaluate the association between the K121Q polymorphism of ENPP1 gene and AR in kidney transplant patients. We analyzed 449 subjects without AR and 98 with AR from a retrospective cohort of kidney transplant patients from Southern Brazil. K121Q polymorphism was genotyped using allelic discrimination-real-time PCR. Cox regression analysis was used to evaluate freedom of AR in kidney transplant patients according to genotypes. Q allele frequency was 17.6% in recipients without AR and 21.9% in those with AR (P = 0.209). Genotype frequencies of the K121Q polymorphism were in Hardy-Weinberg equilibrium in non-AR patients (P = 0.70). The Q/Q genotype (recessive model) was associated with AR (HR = 2.83, 95% CI 1.08–7.45; P = 0.034) after adjusting for confounders factors. Our findings suggest a novel association between the ENPP1 121Q/Q genotype and AR in kidney transplant recipients.
Collapse
Affiliation(s)
- Denise A. Sortica
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
- Postgraduate Program in Medical Sciences: Endocrinology, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
| | - Daisy Crispim
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
- Postgraduate Program in Medical Sciences: Endocrinology, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
| | - Andrea C. Bauer
- Postgraduate Program in Medical Sciences: Endocrinology, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
- Division of Nephrology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
| | - Pamela S. Nique
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
- Postgraduate Program in Medical Sciences: Endocrinology, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
| | - Bruna B. Nicoletto
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
- Life Science Knowledge Area, Universidade de Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil, Nutrition Course, Área do Conhecimento de Ciências da Vida, Universidade de Caxias do Sul (UCS), Caxias do Sul, Brazil
| | - Ricieli P. Crestani
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
| | - Jennifer T. Staehler
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
| | - Roberto C. Manfro
- Division of Nephrology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
| | - Luis H. Canani
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
- Postgraduate Program in Medical Sciences: Endocrinology, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
- * E-mail:
| |
Collapse
|
2
|
Boix F, Bolarín JM, Mrowiec A, Eguía J, Gonzalez-Martinez G, de la Peña J, Galian JA, Alfaro R, Moya-Quiles MR, Legaz I, Campillo JA, Ramírez P, García-Alonso A, Pons JA, Sánchez-Bueno F, Minguela A, Llorente S, Muro M. CD28 biomarker quantification and expression level profiles in CD4 + T-lymphocytes in solid organ transplantation. Transpl Immunol 2017; 42:9-17. [PMID: 28392336 DOI: 10.1016/j.trim.2017.04.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 04/03/2017] [Accepted: 04/03/2017] [Indexed: 02/08/2023]
Abstract
The introduction of anti-calcineurin-based therapies has led to an increase in the one-year survival as well as graft function rates in patients undergoing solid organ transplantation (SOT). Nonetheless, early cellular acute rejection (EAR) incidence still remains a major challenge that irrevocably heads to poor outcomes. The mechanisms underlying CD4 T cell activation in SOT are still under research. In this sense, CD28 co-stimulatory molecule plays a pivotal role triggering CD4 T cell activation as well as survival maintenance. Previous own studies stated the role that CD4+CD28+ circulating T lymphocytes plays before and during EAR episodes. We assessed the percentage as well as the absolute number of CD28 molecules on CD4+ T cells as predictive surrogate biomarker of EAR in a prospective cohort of liver and kidney transplant recipients. Quantitative analysis of CD28 was carried out on whole peripheral blood samples by flow cytometry. Decreased pre-transplant expression of CD28 was associated with EAR in both study groups. Furthermore, the expression of CD28 within the rejected group, experimented an up-regulation upon transplantation. These preliminary results suggest that patients undergoing liver or kidney transplant can be stratified at high risk of EAR according to their CD28 molecule expression on peripheral CD4+ T lymphocytes.
Collapse
Affiliation(s)
- Francisco Boix
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - José Miguel Bolarín
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Anna Mrowiec
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Jorge Eguía
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Gema Gonzalez-Martinez
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Jesús de la Peña
- Department of Pathology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - José A Galian
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Rafael Alfaro
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - María R Moya-Quiles
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Isabel Legaz
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - José A Campillo
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Pablo Ramírez
- Department of Surgery, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Ana García-Alonso
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Jose A Pons
- Department of Surgery, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Francisco Sánchez-Bueno
- Department of Surgery, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Alfredo Minguela
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Santiago Llorente
- Department of Nephrology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain
| | - Manuel Muro
- Department of Immunology, Clinical University Hospital 'Virgen Arrixaca' - IMIB (Murcian Institute of Biomedical Investigation), Murcia, Spain.
| |
Collapse
|
3
|
Zhou M, Hara H, Dai Y, Mou L, Cooper DKC, Wu C, Cai Z. Circulating Organ-Specific MicroRNAs Serve as Biomarkers in Organ-Specific Diseases: Implications for Organ Allo- and Xeno-Transplantation. Int J Mol Sci 2016; 17:ijms17081232. [PMID: 27490531 PMCID: PMC5000630 DOI: 10.3390/ijms17081232] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Revised: 07/25/2016] [Accepted: 07/26/2016] [Indexed: 12/16/2022] Open
Abstract
Different cell types possess different miRNA expression profiles, and cell/tissue/organ-specific miRNAs (or profiles) indicate different diseases. Circulating miRNA is either actively secreted by living cells or passively released during cell death. Circulating cell/tissue/organ-specific miRNA may serve as a non-invasive biomarker for allo- or xeno-transplantation to monitor organ survival and immune rejection. In this review, we summarize the proof of concept that circulating organ-specific miRNAs serve as non-invasive biomarkers for a wide spectrum of clinical organ-specific manifestations such as liver-related disease, heart-related disease, kidney-related disease, and lung-related disease. Furthermore, we summarize how circulating organ-specific miRNAs may have advantages over conventional methods for monitoring immune rejection in organ transplantation. Finally, we discuss the implications and challenges of applying miRNA to monitor organ survival and immune rejection in allo- or xeno-transplantation.
Collapse
Affiliation(s)
- Ming Zhou
- Shenzhen Xenotransplantation Medical Engineering Research and Development Center, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China.
- Institute of Immunology, Zhongshan School of Medicine, Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, Sun Yat-sen University, Guangzhou 510275, China.
| | - Hidetaka Hara
- Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA.
| | - Yifan Dai
- Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing 210029, China.
| | - Lisha Mou
- Shenzhen Xenotransplantation Medical Engineering Research and Development Center, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China.
| | - David K C Cooper
- Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA.
| | - Changyou Wu
- Institute of Immunology, Zhongshan School of Medicine, Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, Sun Yat-sen University, Guangzhou 510275, China.
| | - Zhiming Cai
- Shenzhen Xenotransplantation Medical Engineering Research and Development Center, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518039, China.
| |
Collapse
|